



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 6, 2022 October 14, 2022

Diacomit (stiripentol)

LENGTH OF AUTHORIZATION: Up to one year

REVIEW CRITERIA:

- Patient must be \geq 6 months of age.
- Patient must have a diagnosis of Dravet syndrome (DS).
- Prescribed by or in consultation with a neurologist or epileptologist.
- Medication will be used in adjunct to clobazam.
- Baseline serum hematologic testing has been completed.

CONTINUATION OF THERAPY

- Patient met initial review criteria; **AND**
- Documentation of improved clinical response; **AND**
- Patient has not experienced any treatment-restricting adverse effects; **AND**
- Dosing is appropriate as per labeling or is supported by compendia; **AND**
- Hematologic testing has been completed every 6 months.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as:
 - 250 mg and 500 mg capsule
 - 250 mg and 500 mg powder for oral suspension.